Bazarbachi A, et al. - Among 184 adult patients with Hodgkin lymphoma (HL) with disease recurrence or progression following a matched related or unrelated allogeneic stem cell transplantation (allo-SCT) at European Society for Blood and Marrow Transplantation-participating centers between 2010 and 2014, researchers compared the outcomes of 80 patients who received brentuximab vedotin (BV) salvage therapy vs 104 patients who did not. They noted the highest likelihood of being alive and in CR (40%) at the last follow-up in relation to use of BV before donor lymphocyte infusion. Overall, BV was identified as a safe and effective salvage therapy for this patient population, even following prior exposure to BV.